Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS

Last updated: November 15, 2023
Sponsor: Nanjing First Hospital, Nanjing Medical University
Overall Status: Active - Not Recruiting

Phase

4

Condition

Gastroparesis

Gastrointestinal Diseases And Disorders

Irritable Bowel Syndrome (Ibs)

Treatment

Placebo

DAO supplement

Clinical Study ID

NCT06139744
KY20230915-01
  • Ages 18-65
  • All Genders

Study Summary

This project is a single center, randomized, controlled clinical trial evaluating the effects of DAO enzyme dietary supplement on symptoms of irritable bowel syndrome.

These participants are randomized to either a 4-week group with DAO enzyme dietary supplement or placebo. The participants are required to fill out IBS-SSS and IBS-QOL questionnaires and record their IBS symptom improvement, IBS treatment drug use, compliance and adverse reactions every evening. At the same time, the patients' diet is continuously recorded for 3 days by 24-hour diet review method in Visit 0, Visit 1 and Visit 2, respectively, to inform the patients to avoid large fluctuations in diet structure. On days 0, 14 and 28, the subjects are asked to visit the hospital offline. The staff check with the subjects in detail according to the scale and questionnaire contents, and review the general situation and questionnaire in the previous 2 weeks. On the 7th and 21st day, the staff contact the subjects online to provide guidance and remind the subjects to fill in the scale and questionnaire. In addition, oral mucosal samples, urine and feces will be collected for identifying mutations in the genetic DAO enzyme coding gene, histamine detection and 16sRNA sequencing, respectively.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18-65 years old;
  2. Diagnosed with IBS according to Rome IV diagnostic criteria; Recurrent abdominal painoccurred on an average of at least 1 day per week in the past 3 months and wasassociated with two or more of the following criteria: i. Related to defecation; ii.Associated with changes in bowel frequency; iii. Correlated with fecal morphologicalchanges. The symptoms appeared at least 6 months before diagnosis, and the abovediagnostic criteria were met in the last 3 months.
  3. Voluntarily participate in the experiment and sign the informed consent.

Exclusion

Exclusion Criteria:

  1. Patients with endoscopy examinations which suggest chronic intestinal diseases otherthan IBS, such as inflammatory bowel disease, celiac disease, gastric and duodenalulcers, parasitic or bacterial intestinal infections;
  2. Pregnant and lactating women;
  3. Patients suffering from serious concomitant diseases, such as liver disease,cardiovascular disease, lung disease, kidney disease, tumor;
  4. Alcoholism.

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 4
Study Start date:
November 01, 2023
Estimated Completion Date:
November 30, 2024

Connect with a study center

  • Zhenyu Zhang

    Nanjing, Jiangsu 210000
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.